|
|
|
Insider
Information: |
Shah Rajeev M. |
Relationship: |
Director |
City: |
Boston |
State: |
MA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
49 |
|
Direct
Shares |
20,000 |
|
Indirect Shares
|
277,977,316 |
|
|
Direct
Value |
$116,000 |
|
|
Indirect Value
|
$1,735,037,298 |
|
|
Total
Shares |
277,997,316 |
|
|
Total
Value |
$1,735,153,298 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
22
|
1
|
Stock
price went up :
|
13
|
1
|
Stock
price went down : |
9
|
0
|
|
|
|
Gain/Loss Ratio : |
1.4
|
1.0
|
Percentage
Gain/Loss : |
31.8%
|
1.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Ra Pharmaceuticals, Inc. |
RARX |
Director, 10% Owner |
2016-10-31 |
0 |
2020-04-02 |
0 |
Premium* |
|
Kalvista Pharmaceuticals Inc |
KALV |
Director, 10% Owner |
2016-11-21 |
0 |
2017-10-12 |
1,441,070 |
Premium* |
|
Kala Pharmaceuticals, Inc. |
KALA |
10% Owner |
2021-06-17 |
20,000 |
2022-05-26 |
7,039,613 |
Premium* |
|
Solid Biosciences Inc |
SLDB |
Director, 10% Owner |
2018-01-30 |
0 |
2022-12-02 |
109,661 |
Premium* |
|
Eidos Therapeutics, Inc. |
EIDX |
Director |
2018-06-22 |
0 |
2018-06-22 |
2,162,671 |
Premium* |
|
Satsuma Pharmaceuticals, Inc. |
STSA |
Director, 10% Owner |
2019-09-17 |
0 |
2023-06-06 |
0 |
Premium* |
|
Phathom Pharmaceuticals, Inc. |
PHAT |
10% Owner |
|
0 |
2021-03-11 |
3,115,008 |
Premium* |
|
89bio, Inc. |
ETNB |
Director, 10% Owner |
2019-11-11 |
0 |
2024-04-11 |
14,175,398 |
Premium* |
|
Synthorx, Inc. |
THOR |
10% Owner |
2020-01-23 |
0 |
2020-01-23 |
0 |
Premium* |
|
Black Diamond Therapeutics, Inc. |
BDTX |
Director |
2021-05-20 |
0 |
2023-07-05 |
3,525,754 |
Premium* |
|
Scpharmaceuticals Inc. |
SCPH |
10% Owner |
2020-02-14 |
0 |
2021-03-15 |
2,727,446 |
Premium* |
|
Verastem, Inc. |
VSTM |
10% Owner |
|
0 |
2020-06-25 |
16,142,051 |
Premium* |
|
Enliven Therapeutics Ord Shs |
ELVN |
Former 10% owner |
2020-03-16 |
0 |
2023-02-23 |
2,122,465 |
Premium* |
|
TG Therapeutics Inc |
TGTX |
10% Owner |
|
0 |
2020-09-09 |
12,629,868 |
Premium* |
|
Vaxcyte, Inc. |
PCVX |
10% Owner |
|
0 |
2020-10-08 |
5,001,593 |
Premium* |
|
Forma Therapeutics Holdings, Inc., |
FMTX |
10% Owner |
2020-06-23 |
0 |
2022-10-14 |
0 |
Premium* |
|
Rhythm Pharmaceuticals, Inc. |
RYTM |
10% Owner |
2020-06-25 |
0 |
2020-07-02 |
5,140,408 |
Premium* |
|
Akouos, Inc. |
AKUS |
10% Owner |
2020-06-30 |
0 |
2020-06-30 |
2,281,249 |
Premium* |
|
Nkarta, Inc. |
NKTX |
Director, 10% Owner |
2020-07-14 |
0 |
2024-03-27 |
10,805,129 |
Premium* |
|
Pandion Therapeutics, Inc. |
PAND |
10% Owner |
2020-07-21 |
0 |
2020-07-21 |
1,770,023 |
Premium* |
|
Inozyme Pharma, Inc. |
INZY |
10% Owner |
2020-07-28 |
0 |
2020-07-28 |
2,003,653 |
Premium* |
|
Iteos Therapeutics, Inc. |
ITOS |
Former 10% Owner |
2020-07-28 |
0 |
2024-05-12 |
3,517,259 |
Premium* |
|
Dyne Therapeutics, Inc. |
DYN |
10% Owner |
2020-09-21 |
0 |
2020-09-21 |
2,805,045 |
Premium* |
|
Pmv Pharmaceuticals, Inc. |
PMVP |
10% Owner |
2020-09-29 |
0 |
2020-09-29 |
1,710,265 |
Premium* |
|
Cardiff Oncology Inc |
CRDF |
10% Owner |
|
0 |
2020-09-30 |
3,290,000 |
Premium* |
|
Orchard Therapeutics Plc |
ORTX |
10% Owner |
2020-08-10 |
0 |
2020-09-24 |
9,880,865 |
Premium* |
|
Viridian Therapeutics Ors Shs |
VRDN |
10% Owner |
|
0 |
2020-12-07 |
410,686 |
Premium* |
|
Iterum Therapeutics Plc |
ITRM |
10% Owner |
2021-02-04 |
0 |
2021-02-04 |
11,651,597 |
Premium* |
|
Vor Biopharma Inc. |
VOR |
Director, 10% Owner |
2021-02-09 |
0 |
2022-12-09 |
22,748,880 |
Premium* |
|
Werewolf Therapeutics, Inc. |
HOWL |
Director, 10% Owner |
2021-05-04 |
0 |
2023-01-06 |
6,144,881 |
Premium* |
|
Aerovate Therapeutics, Inc. |
AVTE |
Director, 10% Owner |
2021-07-02 |
0 |
2024-06-17 |
9,192,092 |
Premium* |
|
Acumen Pharmaceuticals, Inc. |
ABOS |
Director, 10% Owner |
2021-07-06 |
0 |
2023-07-21 |
14,932,063 |
Premium* |
|
Cytek Biosciences, Inc. |
CTKB |
Director, 10% Owner |
2021-07-27 |
0 |
2022-03-15 |
13,381,054 |
Premium* |
|
Icosavax, Inc. |
ICVX |
Director, 10% Owner |
2021-08-02 |
0 |
2024-02-19 |
0 |
Premium* |
|
Eliem Therapeutics, Inc. |
ELYM |
Director, 10% Owner |
|
0 |
2024-06-27 |
5,417,638 |
Premium* |
|
Rxsight, Inc. |
RXST |
10% Owner |
|
0 |
2021-08-03 |
3,052,796 |
Premium* |
|
Tyra Biosciences, Inc. |
TYRA |
Director, 10% Owner |
2021-09-17 |
0 |
2024-02-06 |
10,416,609 |
Premium* |
|
Dice Therapeutics, Inc. |
DICE |
Former 10% owners and ... |
2021-09-17 |
0 |
2023-08-09 |
0 |
Premium* |
|
An2 Therapeutics Ord Shs |
ANTX |
10% Owner |
2022-03-29 |
0 |
2024-08-09 |
300,853 |
Premium* |
|
Pepgen Inc. |
PEPG |
Director, 10% Owner |
2022-05-10 |
0 |
2024-02-09 |
10,689,545 |
Premium* |
|
Wave Life Sciences Ltd. |
WVE |
Director, 10% Owner |
2022-06-16 |
0 |
2024-08-12 |
18,218,124 |
Premium* |
|
Fulcrum Therapeutics, Inc. |
FULC |
10% Owner |
|
0 |
2024-08-21 |
3,109,704 |
Premium* |
|
Silverback Therapeutics, Inc. |
SBTX |
Director, 10% Owner |
2022-11-08 |
0 |
2024-03-27 |
10,860,977 |
Premium* |
|
Acrivon Therapeutics, Inc. |
ACRV |
Director, 10% Owner |
2022-11-17 |
0 |
2024-04-11 |
8,340,508 |
Premium* |
|
Mineralys Therapeutics, Inc. |
MLYS |
Director |
2023-02-14 |
0 |
2024-02-12 |
4,850,984 |
Premium* |
|
Janux Therapeutics, Inc. |
JANX |
Director, 10% Owner |
2023-07-19 |
0 |
2024-06-26 |
9,168,152 |
Premium* |
|
Lenz Therapeutics |
LENZ |
Director, 10% Owner |
2024-03-21 |
0 |
2024-03-21 |
694,755 |
Premium* |
|
Boundless Bio, Inc. |
BOLD |
10% Owner |
2024-04-02 |
0 |
2024-04-02 |
295,844 |
Premium* |
|
Cidara Therapeutics, Inc. |
CDTX |
Director |
2024-07-19 |
0 |
2024-07-19 |
703,080 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
223 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 2 of 9
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
ELVN |
Enliven Therapeutics Ord ... |
10% Owner |
|
2020-03-16 |
4 |
A |
$0.00 |
$0 |
I/I |
829,348 |
829,348 |
0 |
- |
|
PHAT |
Phathom Pharmaceuticals, ... |
10% Owner |
|
2020-03-27 |
4 |
B |
$24.60 |
$738,000 |
I/I |
30,000 |
3,676,808 |
1.5 |
- |
|
PHAT |
Phathom Pharmaceuticals, ... |
10% Owner |
|
2020-03-31 |
4 |
B |
$24.55 |
$751,264 |
I/I |
30,600 |
3,707,408 |
1.5 |
- |
|
PHAT |
Phathom Pharmaceuticals, ... |
10% Owner |
|
2020-04-01 |
4 |
B |
$24.86 |
$2,923,642 |
I/I |
117,600 |
3,825,008 |
1.5 |
- |
|
RARX |
Ra Pharmaceuticals, Inc. |
Director |
|
2020-04-02 |
4 |
D |
$48.00 |
$233,196,480 |
I/I |
(4,858,260) |
0 |
0 |
- |
|
VSTM |
Verastem, Inc. |
10% Owner |
|
2020-04-27 |
4 |
S |
$2.31 |
$3,002,099 |
I/I |
(1,301,300) |
17,303,351 |
0 |
- |
|
FMTX |
Forma Therapeutics Holdin... |
10% Owner |
|
2020-06-23 |
4 |
B |
$20.00 |
$80,000,000 |
I/I |
4,000,000 |
9,011,651 |
1.5 |
- |
|
FMTX |
Forma Therapeutics Holdin... |
10% Owner |
|
2020-06-23 |
4 |
A |
$0.00 |
$0 |
I/I |
5,011,651 |
5,011,651 |
0 |
- |
|
VSTM |
Verastem, Inc. |
10% Owner |
|
2020-06-25 |
4 |
S |
$1.91 |
$2,219,941 |
I/I |
(1,161,300) |
16,142,051 |
0 |
- |
|
RYTM |
Rhythm Pharmaceuticals, I... |
10% Owner |
|
2020-06-25 |
4 |
S |
$25.05 |
$289,768 |
I/I |
(11,568) |
5,410,744 |
0 |
- |
|
RYTM |
Rhythm Pharmaceuticals, I... |
10% Owner |
|
2020-06-26 |
4 |
S |
$23.31 |
$2,020,848 |
I/I |
(86,706) |
5,324,038 |
0 |
- |
|
RYTM |
Rhythm Pharmaceuticals, I... |
10% Owner |
|
2020-06-29 |
4 |
S |
$22.19 |
$1,154,999 |
I/I |
(52,049) |
5,271,989 |
0 |
- |
|
AKUS |
Akouos, Inc. |
10% Owner |
|
2020-06-30 |
4 |
B |
$17.00 |
$14,025,000 |
I/I |
825,000 |
2,281,249 |
1.5 |
- |
|
RYTM |
Rhythm Pharmaceuticals, I... |
10% Owner |
|
2020-06-30 |
4 |
S |
$22.15 |
$1,371,237 |
I/I |
(61,901) |
5,210,088 |
0 |
- |
|
AKUS |
Akouos, Inc. |
10% Owner |
|
2020-06-30 |
4 |
A |
$0.00 |
$0 |
I/I |
1,456,249 |
1,456,249 |
0 |
- |
|
RYTM |
Rhythm Pharmaceuticals, I... |
10% Owner |
|
2020-07-01 |
4 |
S |
$21.87 |
$558,311 |
I/I |
(25,527) |
5,184,561 |
0 |
- |
|
RYTM |
Rhythm Pharmaceuticals, I... |
10% Owner |
|
2020-07-02 |
4 |
S |
$22.04 |
$972,969 |
I/I |
(44,153) |
5,140,408 |
0 |
- |
|
ETNB |
89bio, Inc. |
10% Owner |
|
2020-07-08 |
4 |
B |
$27.50 |
$7,562,500 |
I/I |
275,000 |
3,436,214 |
1.5 |
- |
|
NKTX |
Nkarta, Inc. |
10% Owner |
|
2020-07-14 |
4 |
B |
$18.00 |
$59,999,994 |
I/I |
3,333,333 |
5,605,129 |
1.5 |
- |
|
NKTX |
Nkarta, Inc. |
10% Owner |
|
2020-07-14 |
4 |
A |
$0.00 |
$0 |
I/I |
2,271,796 |
2,271,796 |
0 |
- |
|
PAND |
Pandion Therapeutics, Inc... |
10% Owner |
|
2020-07-21 |
4 |
B |
$18.00 |
$6,499,998 |
I/I |
361,111 |
1,770,023 |
1.5 |
- |
|
PAND |
Pandion Therapeutics, Inc... |
10% Owner |
|
2020-07-21 |
4 |
A |
$0.00 |
$0 |
I/I |
1,408,912 |
1,408,912 |
0 |
- |
|
ITOS |
Iteos Therapeutics, Inc. |
10% Owner |
|
2020-07-28 |
4 |
A |
$0.00 |
$0 |
I/I |
2,992,259 |
2,992,259 |
0 |
- |
|
ITOS |
Iteos Therapeutics, Inc. |
10% Owner |
|
2020-07-28 |
4 |
B |
$19.00 |
$27,075,000 |
I/I |
1,425,000 |
4,417,259 |
1.5 |
- |
|
INZY |
Inozyme Pharma, Inc. |
10% Owner |
|
2020-07-28 |
4 |
B |
$16.00 |
$9,600,000 |
I/I |
600,000 |
2,003,653 |
1.5 |
- |
|
223 Records found
|
|
Page 2 of 9 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|